SUPN Stock Cash Flow Statements

Supernus Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Supernus Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-09-30	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31

cash flows from operating activities
net earnings	22,499,000	-11,827,000	15,328,000	38,497,000	19,916,000	124,000	1,175,000	-15,976,000	-831,000	16,948,000	25,481,000	1,749,000	7,865,000	25,616,000	2,442,000	21,562,000	23,726,000	5,694,000	30,768,000	39,997,000	34,667,000	21,518,000	33,129,000	28,860,000	32,727,000	18,340,000	28,011,000	30,737,000	26,352,000
adjustments to reconcile net earnings to net cash from operating activities:
depreciation and amortization	21,358,000	20,383,000	18,845,000	20,102,000	20,718,000	20,749,000	21,676,000	21,857,000	20,725,000	20,601,000	20,849,000	21,775,000	21,557,000	21,362,000	12,707,000	6,675,000	6,621,000	6,592,000	5,520,000	7,577,000	3,312,000	1,732,000	1,630,000	1,674,000	1,676,000	1,679,000	1,884,000	1,780,000	1,707,000	4,378,000	1,343,000	741,000	611,000	688,000	429,000	220,000	217,000	214,000	241,000	233,000	227,000	200,000	164,000	162,000	212,000	213,000	225,000
amortization of premium/discount on marketable securities	-32,000	-1,074,000	-674,000	966,000	-363,000	1,894,000	727,000	68,000	139,000	-1,056,000	18,000	2,147,000	1,428,000	-360,000	1,263,000	1,526,000	-665,000	-1,706,000	328,000	-4,201,000	1,435,000	-451,000	-1,146,000	-1,564,000					89,000
change in fair value of contingent consideration	0	7,660,000	356,000	-1,016,000	-4,355,000	-1,095,000		-456,000	790,000	-1,647,000		486,000	743,000	665,000		80,000	-8,750,000	1,020,000
share-based compensation expense	7,507,000	8,068,000	7,632,000	7,674,000	6,552,000	5,897,000	6,445,000	7,920,000	6,088,000	6,306,000	4,261,000	4,985,000	4,297,000	4,025,000	4,036,000	4,027,000	5,476,000	4,371,000	3,121,000	4,490,000	4,962,000	3,988,000	3,623,000	3,914,000	4,022,000	3,287,000	2,597,000	3,068,000	2,635,000	2,360,000	2,260,000	1,827,000	1,483,000	1,612,000	1,359,000	1,132,000	1,119,000	901,000
deferred income tax benefit	-7,162,000	-3,990,000	-72,000	-6,467,000	-8,115,000	-5,482,000	-10,459,000	-9,266,000	-5,554,000	-435,000				-13,011,000					848,000	2,782,000	-3,600,000	538,000	-4,143,000	-2,550,000	582,000	279,000						4,258,000
inventory valuation write-down	920,000	547,000
payment of contingent consideration	0	-4,900,000									0	0	0	-22,900,000
other noncash adjustments	1,953,000	1,826,000	-756,000	1,658,000	4,174,000	2,449,000	3,435,000	2,058,000	5,968,000	2,459,000	3,655,000	9,170,000	-1,271,000	84,000	-1,398,000	629,000	551,000	-1,202,000
changes in operating assets and liabilities:
accounts receivable	4,809,000	-3,563,000	3,331,000	7,086,000	-4,760,000	-3,579,000	-2,390,000	-5,209,000	4,393,000	21,971,000	-1,408,000	-5,865,000	-12,905,000	3,812,000	-3,485,000	3,747,000	-10,200,000	13,805,000	-7,767,000	-6,409,000	11,392,000	-31,823,000	-593,000	-2,095,000	-4,574,000	23,013,000						2,642,000										-6,671,000
inventories	4,887,000	4,731,000	3,187,000	4,604,000	6,025,000	1,990,000	5,028,000	6,912,000	-3,979,000	-1,851,000	-11,554,000	-8,146,000	4,310,000	-2,468,000	-5,249,000	-1,381,000	-6,902,000	-1,048,000	-4,687,000	-7,126,000	-521,000	2,210,000	-1,124,000	520,000						1,676,000
prepaid expenses and other assets	-2,502,000	7,372,000	-10,810,000	-1,753,000	728,000	-7,517,000	7,804,000	20,406,000	-28,203,000	-341,000	9,205,000	1,232,000	805,000	1,061,000	4,953,000	4,652,000	-17,635,000	-368,000															-929,000	1,729,000	260,000			38,000				96,000	-1,051,000	133,000
accrued product returns and rebates	10,783,000	1,428,000	-419,000	-5,995,000	7,893,000	12,952,000	-8,199,000	13,647,000	974,000	-3,813,000	-6,805,000	12,709,000	5,580,000	7,457,000	-1,354,000	-41,550,000	44,862,000	2,544,000	-10,780,000	-7,132,000	16,474,000	11,824,000	9,579,000	2,116,000
accounts payable and other liabilities	-6,485,000	3,938,000	-418,000	-11,827,000	-12,789,000	10,019,000	-269,000	-6,086,000	-19,384,000	-10,548,000	-6,504,000	-24,422,000	41,242,000	-29,479,000	33,905,000	-10,047,000	4,329,000	-10,008,000
net cash from operating activities	58,535,000	30,599,000	44,406,000	53,520,000	35,624,000	38,401,000	44,958,000	35,875,000	-18,874,000	49,126,000	27,564,000	13,841,000	71,119,000	4,302,000	48,763,000	-4,110,000	46,274,000	36,200,000	31,933,000	5,599,000	91,951,000	8,916,000	43,791,000	37,658,000	28,687,000	32,993,000	62,448,000	6,556,000	27,133,000	39,005,000	25,942,000	13,358,000	28,239,000			-2,983,000	14,669,000	503,000				-15,550,000
capex	-455,000	-327,000	-213,000	-200,000	-64,000	-248,000	0	-150,000	-159,000	-278,000	10,000	-147,000	0	-851,000	-40,000	0	0	-1,508,000	-215,000	-162,000	-535,000	-2,537,000	-2,029,000	-462,000	0	0	0	0	0	0	0	0	0			0	0	0				-377,000
free cash flows	58,080,000	30,272,000	44,193,000	53,320,000	35,560,000	38,153,000	44,958,000	35,725,000	-19,033,000	48,848,000	27,574,000	13,694,000	71,119,000	3,451,000	48,723,000	-4,110,000	46,274,000	34,692,000	31,718,000	5,437,000	91,416,000	6,379,000	41,762,000	37,196,000	28,687,000	32,993,000	62,448,000	6,556,000	27,133,000	39,005,000	25,942,000	13,358,000	28,239,000			-2,983,000	14,669,000	503,000				-15,927,000
cash flows from investing activities
purchases of marketable securities	-140,556,000	-118,557,000	-145,405,000	-224,928,000	-123,980,000	-193,700,000					-66,325,000	-134,162,000	-108,440,000	-98,063,000	-3,939,000	-74,362,000	-114,209,000	-119,063,000	-8,000,000	-72,508,000	0	-15,382,000	-48,586,000	-96,195,000																		-17,964,000
maturities of marketable securities	110,404,000	156,201,000	132,980,000	148,117,000
purchases of property and equipment	-455,000	-327,000	-213,000	-200,000	-64,000	-248,000		-150,000	-159,000	-278,000							0	-1,508,000	-215,000	-162,000	-535,000	-2,537,000	-2,029,000	-462,000																		-377,000
net cash from investing activities	-30,607,000	37,317,000	-12,638,000	-77,011,000	-48,594,000	-51,624,000	-65,981,000	34,634,000	60,296,000	239,780,000	-48,765,000	-82,232,000	-15,679,000	-69,987,000	76,130,000	-5,704,000	-80,894,000	-71,445,000	49,345,000	-11,302,000	-108,180,000	35,438,000	19,438,000	-8,355,000															-973,000			4,606,000
cash flows from financing activities
proceeds from issuance of common stock	3,276,000	2,042,000	6,877,000	3,462,000	1,659,000	2,910,000	3,082,000	-230,000	1,947,000	1,811,000	2,829,000	6,455,000	2,273,000	866,000	1,575,000	524,000	2,749,000	2,247,000	2,815,000	77,000	1,437,000	32,000	1,263,000	242,000	1,640,000	783,000	828,000	6,646,000	2,857,000	2,346,000	1,560,000	604,000	260,000	871,000	124,000	58,000	862,000	147,000	14,000	245,000	6,000	11,000	217,000	1,936,000			49,000
employee taxes paid related to net share settlement of equity awards	-46,000	-3,341,000	-987,000	-387,000	-1,000	-1,340,000
net cash from financing activities	935,000	-21,399,000	5,890,000	3,075,000	1,658,000	1,570,000	1,092,000	-230,000	-478,916,000	80,174,000	2,829,000	6,455,000	2,273,000	-22,034,000	-136,740,000	1,324,000	2,749,000	2,247,000	3,069,000	-979,000	1,437,000	32,000	1,263,000	242,000	1,640,000	783,000	828,000	6,646,000	367,713,000	2,346,000	1,560,000	604,000	260,000	871,000	124,000	58,000	862,000	147,000	14,000	245,000	5,000	-18,000			-2,225,000
net change in cash and cash equivalents	28,863,000	46,517,000	37,658,000	-20,416,000			-19,931,000				-18,372,000	-61,936,000	57,713,000	-87,719,000	-11,847,000	-8,490,000	-31,871,000	-32,998,000	84,347,000	-6,682,000	-14,792,000	44,386,000	64,492,000	29,545,000					343,836,000				18,803,000									-10,962,000
cash and cash equivalents at beginning of year	0	69,331,000	0	0	0	75,054,000	0	0	0	93,120,000	0	0	0	203,434,000	0	0	0	288,640,000	0	0	0	181,381,000	0	0	0	192,248,000	0	0	100,304,000
cash and cash equivalents at end of period	28,863,000	115,848,000		-20,416,000				70,279,000				-61,936,000	57,713,000	115,715,000		-8,490,000	-31,871,000	255,642,000	84,347,000	-6,682,000	-14,792,000	225,767,000	64,492,000	29,545,000	-35,434,000	122,778,000	88,613,000	-408,935,000	444,140,000	20,187,000	2,138,000	59,599,000	18,149,000	16,326,000	19,830,000	-6,816,000	7,300,000	25,810,000	25,824,000	-296,000	12,252,000	-10,962,000	14,998,000	18,909,000	-23,830,000	31,376,000	15,866,000
supplemental cash flow information
cash paid for income taxes	12,423,000	274,000	12,911,000	19,581,000	20,426,000	336,000	9,547,000	6,621,000	20,231,000	203,000		6,015,000	8,065,000	478,000		4,415,000	20,395,000	301,000
cash paid for operating leases		3,892,000		5,086,000	4,136,000	4,002,000	3,870,000	4,533,000	5,252,000	3,457,000	3,336,000	3,309,000	3,289,000	2,949,000	4,295,000	3,577,000	2,202,000	1,834,000
noncash investing and financing activities
lease assets obtained for new operating leases				22,000	921,000	2,604,000		1,965,000	1,337,000	2,601,000		761,000
other income from navitor											0	0	0	-12,888,000
intangible asset impairment charges
amortization of deferred financing costs and debt discount							0	0	0	532,000	530,000	529,000	527,000	526,000	4,464,000	4,405,000	4,345,000	4,287,000	4,230,000	4,172,000	4,118,000	4,061,000	4,007,000	3,953,000	3,900,000	3,848,000	3,745,000	3,695,000	612,000							122,000	150,000	374,000	512,000	513,000	574,000	1,183,000	804,000	83,000
realized gains from sales of marketable securities			0								0	-1,000			-126,000	-2,000	-3,000	-216,000	-716,000	-320,000
proceeds from credit line
payments on credit line
payment on convertible notes							0	0
cash and cash equivalents at end of year
cash paid for interest on debt							0	0
property and equipment additions from utilization of tenant improvement allowance											0	0	31,000	549,000
noncash operating activities
sales and maturities of marketable securities						142,324,000	35,604,000	34,784,000	60,455,000	240,058,000	17,550,000	52,077,000	92,185,000	28,927,000	377,963,000	68,702,000	34,265,000	49,579,000	59,001,000	61,485,000	204,579,000	53,357,000	68,703,000	88,302,000	49,022,000	47,143,000	25,805,000	12,123,000	7,343,000	10,633,000	7,279,000	5,140,000	6,740,000	8,258,000	7,400,000	11,809,000	13,131,000	8,731,000	14,894,000	17,997,000	9,096,000	23,253,000	11,547,000	12,866,000	9,742,000	7,381,000	293,000
net change in cash, cash equivalents, and restricted cash						-11,653,000			-437,494,000	369,080,000
cash, cash equivalents, and restricted cash at end of period						63,401,000				462,200,000
noncash operating and investing activities
navitor investment r&d expense															0	0	0	15,000,000
changes in fair value of contingent consideration
contingent consideration											0	0	0	-2,100,000
acquisition of uswm, net of cash acquired															0	0			-1,341,000	0
acquisition of adamas, net of cash acquired
distribution from navitor
purchase of property and equipment and deferred legal fees paid											10,000	-147,000			-40,000
proceeds from line of credit							0	0	0	93,000,000
payments on line of credit							0	0	-78,363,000	-14,637,000
proceeds from governmental loan and grant															0
repayment of acquired adamas loan
supplemental cash flow information:
noncash investing and financing activity:
contingent consideration liability related to acquisitions
deferred legal fees and fixed assets included in accounts payable and accrued expenses																		160,000	-139,000	-13,000	-343,000	708,000	1,337,000
cash paid for interest on convertible notes											0	1,258,000	0	1,258,000	629,000	629,000	0	1,258,000	0	1,258,000	0	1,258,000	0	1,258,000	0	1,258,000
distribution from (investment in) navitor
payments on finance lease liability																			254,000
income taxes paid																					283,000	324,000	15,607,000	11,138,000	23,995,000	800,000	651,000	23,656,000	5,623,000
lease assets and tenant receivable obtained for new operating leases														27,000											14,591,000	17,136,000
lease assets obtained for new finance lease
deferred income tax provision												-2,507,000				1,567,000	519,000	-2,565,000												1,642,000
purchases of property and equipment and deferred legal fees paid														-851,000
investment in navitor pharmaceuticals, inc.																			0	0
contingent consideration liability accrued in uswm acquisition																				200,000
lease assets and tenant receivable obtained for new leases																		1,432,000		487,000
deferred legal fees																	0	-453,000	-100,000	-117,000			1,350,000	0
lease assets obtained for new leases
proceeds from issuance of convertible notes																											0	0	402,500,000
convertible notes issuance financing costs
proceeds from issuance of warrants																											0	0	65,688,000
cash paid for biscayne acquisition
contingent consideration liability related to uswm acquisition
noncash interest expense																				1,645,000	1,504,000	1,366,000	1,444,000
noncash royalty revenue																				-2,402,000	-2,351,000	-1,567,000	-1,899,000
noncash operating lease cost																				757,000	851,000	991,000	966,000
prepaid expenses and other current assets																				-4,551,000	-4,313,000	-454,000	1,513,000	-655,000
other noncurrent assets																				-1,240,000			0
accounts payable																				5,672,000	-182,000	-7,017,000	7,296,000	-1,220,000	-3,159,000	4,045,000										-1,706,000
accrued expenses and other current liabilities																				-2,503,000	14,547,000	-3,634,000	-4,931,000	2,427,000
income taxes payable																				-25,051,000	15,859,000	6,654,000	-2,375,000	2,144,000	-14,559,000	4,856,000			327,000
other liabilities																				-758,000	-1,711,000	-1,020,000	-3,185,000
loss on extinguishment of debt																														91,000	103,000	101,000	0	0	382,000	25,000	241,000	2,134,000	860,000	39,000	1,693,000	0
change in fair value of derivative liability																																					-1,000	49,000
deferred licensing revenue																																	-53,000	-52,000	300,000							623,000	-127,000	373,000
purchases of convertible note hedges
conversion of convertible notes and interest make-whole																														1,562,000	1,961,000	1,023,000	0	0	2,138,000	963,000	3,880,000	21,176,000
unsettled purchase of marketable securities included in accrued expenses
property and equipment acquired under build-to-suit lease transaction
interest capitalized during construction period for build-to-suit lease transaction
facility lease financing obligation
realized loss on sales of securities
amortization of operating lease assets																									351,000	879,000
non-cash interest expense																									1,414,000	1,437,000
non-cash royalty revenue
other non-current assets
other non-current liabilities																											-1,783,000	889,000	984,000	417,000					73,000				230,000			-13,000	434,000	44,000	125,000
cash paid for amounts included in the measurement of lease liabilities
operating cash flows from operating leases																									1,391,000	1,313,000
non-cash investing and financing activities
deferred legal fees included in accounts payable and accrued expenses																									30,000	250,000	-200,000	176,000	304,000	-547,000	-4,700,000	6,584,000	2,383,000	1,758,000	3,779,000
non-cash interest expense on non-recourse liability related to sale of future royalties																											1,191,000	1,204,000	701,000	155,000	160,000	959,000
accrued sales deductions																											15,926,000	-2,990,000	4,691,000	12,151,000	4,171,000	1,507,000
accrued expenses																											3,002,000										5,900,000	366,000
cash paid for interest																														0			0			0			0			0	365,000	610,000
non-cash investing and financing activity:
purchases of property, plant and equipment
non-cash financial activity:
net income																														15,961,000	17,368,000	10,297,000	61,897,000	10,018,000	4,987,000	4,222,000	2,006,000	917,000	27,858,000	3,201,000	-15,543,000	-24,096,000	-27,357,000	-18,414,000	-13,483,000	-10,011,000	-9,277,000
adjustments to reconcile net income to net cash from operating activities:
non-cash interest expense, net/interest (income)
net increase in cash and cash equivalents
cash and cash equivalents at beginning of period																														0	0	66,398,000	-654,000	0	34,152,000	0	0	36,396,000	0	0	32,980,000	0	0	40,302,000	0	0	48,544,000
noncash financial activity:
accrued income taxes payable																															-67,000	1,668,000
unrealized loss on marketable securities
non-cash interest expense on liability related to sale of future royalties
accrued sales deduction																																	4,675,000	6,322,000	1,903,000
exercise of warrants
non-cash interest expense, net/ interest income
non cash interest expense, net/interest income																																			155,000
unrealized (gain) loss on marketable securities
deferred product revenue																																									4,389,000	6,398,000	416,000	3,551,000
cash settlement of debt to equity conversion
deferred legal fees included in accrued expenses
adjustments to reconcile income from continuing operations to net cash from operating activities:
unrealized gain on marketable securities																																					-86,000	89,000		0	1,000					-2,000	8,000
adjustments to reconcile income to net cash from operating activities:
change in fair value of derivative liabilities																																										4,152,000
stock-based compensation expense																																							704,000	652,000	667,000	491,000	432,000	337,000	130,000	53,000	52,000
interest receivable																																										-192,000
accounts payable and accrued expenses																																							2,939,000			2,998,000	1,103,000	238,000
capitalized patent defense costs
proceeds from convertible debt issuance																																										0
repayment of secured notes payable																																										0
financing costs and underwriters discounts																																										-29,000
conversion of convertible notes																																							4,211,000	258,000	10,418,000
initial value of interest make-whole derivative issued in connection with the convertible debt
initial value of conversion option reported in equity
adjustments to reconcile loss to net cash from operating activities:
initial value of interest make-whole derivative
issued in connection with the convertible debt																																										0
inventory																																										-873,000
adjustments to reconcile loss to net cash used
in operating activities:
unrealized (loss) on marketable securities
patent defense costs
conversion of preferred stock
initial value of conversion reported in equity
change in fair value of warrant liability																																													294,000	144,000	328,000
income from discontinued operations
income from continuing operations
gain on sale of property and equipment
amortization of deferred financing costs																																													84,000	81,000	83,000
interest payable																																													-20,000	-12,000	133,000
deferred revenue
net cash from operating activities from continuing operations
net cash from operating activities from discontinued operations
net cash from investing activities from continuing operations
net cash from investing activities from discontinued operations
proceeds from issuance of common stock, net of underwriters discounts
proceeds from issuance of (payments on) secured notes payable
financing costs
net cash from financing activities from continuing operations																																													-2,225,000
net cash from financing activities from discontinued operations
cash paid for interest-continuing operations
cash paid for interest-discontinued operations
noncash conversion of preferred stock to common stock																																													0
proceeds from issuance of common stock, net of offering costs
proceeds from issuance of secured notes payable
cash paid for interest—continuing operations																																														800,000	688,000
cash paid for interest—discontinued operations
deferred financing costs

We provide you with 20 years of cash flow statements for Supernus Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Supernus Pharmaceuticals stock. Explore the full financial landscape of Supernus Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Supernus Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.